For much of the past year, the UK’s medicines pricing debate has cast a long shadow over the life sciences sector. The deadlock over NHS rebates – and the uncertainty surrounding the successor to VPAG ...
In Q3 of FY26, the company posted a net profit of ₹553.60 Crore. This is a growth of 7.30% on a year-on-year basis.
The firm posted a revenue growth of 10% to ₹71,450 Crore in Q3FY26. However, the company missed street estimates of ₹75,011 Crore.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results